Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Immune response to 2009 H1N1 vaccine in HIV-infected adults in Northern Thailand.

Chotirosniramit N, Sugandhavesa P, Aurpibul L, Thetket S, Kosashunhanan N, Supindham T, Wongkulab P, Kaewpoowat Q, Chaiklang K, Kaewthip O, Sroysuwan P, Wongthanee A, Lerdsamran H, Puthavathana P, Suparatpinyo K.

Hum Vaccin Immunother. 2012 Dec 1;8(12):1854-9. doi: 10.4161/hv.21820. Epub 2012 Aug 21.

2.

Immunogenicity and safety of monovalent influenza A (H1N1) 2009 in HIV-infected Thai children.

Phongsamart W, Sirisanthana V, Wittawatmongkol O, Maleesatharn A, Sudjaritruk T, Chearskul P, Aurpibul L, Sirisanthana T, Chokephaibulkit K.

Vaccine. 2011 Nov 3;29(47):8705-11. doi: 10.1016/j.vaccine.2011.08.101. Epub 2011 Sep 3.

PMID:
21893147
3.

Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients.

Chang YT, Guo CY, Tsai MS, Cheng YY, Lin MT, Chen CH, Shen D, Wang JR, Sung JM.

Vaccine. 2012 Jul 13;30(33):5009-18. doi: 10.1016/j.vaccine.2012.05.016. Epub 2012 May 30.

PMID:
22658967
4.

Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial.

Yang WH, Dionne M, Kyle M, Aggarwal N, Li P, Madariaga M, Godeaux O, Vaughn DW.

Vaccine. 2013 Sep 13;31(40):4389-97. doi: 10.1016/j.vaccine.2013.07.007. Epub 2013 Jul 12.

5.

Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals.

Lagler H, Grabmeier-Pfistershammer K, Touzeau-Römer V, Tobudic S, Ramharter M, Wenisch J, Gualdoni GA, Redlberger-Fritz M, Popow-Kraupp T, Rieger A, Burgmann H.

PLoS One. 2012;7(5):e36773. doi: 10.1371/journal.pone.0036773. Epub 2012 May 21.

6.

Safety and immunogenicity of a monovalent MF59®-adjuvanted A/H1N1 vaccine in HIV-infected children and young adults.

Palma P, Romiti ML, Bernardi S, Pontrelli G, Mora N, Santilli V, Tchidjou HK, Aquilani A, Cotugno N, Alghisi F, Lucidi V, Rossi P, Douagi I.

Biologicals. 2012 Mar;40(2):134-9. doi: 10.1016/j.biologicals.2011.12.001. Epub 2012 Jan 20.

PMID:
22261282
7.

Improved serological response to H1N1 monovalent vaccine associated with viral suppression among HIV-1-infected patients during the 2009 influenza (H1N1) pandemic in the Southern Hemisphere.

Maruszak H, Jeganathan S, Smith DE, Robertson P, Barnes T, Furner V.

HIV Med. 2012 Jul;13(6):352-7. doi: 10.1111/j.1468-1293.2011.00987.x. Epub 2012 Feb 2.

8.

Antibody response to the non-adjuvanted and adjuvanted influenza A H1N1/09 monovalent vaccines in renal transplant recipients.

Salles MJ, Sens YA, Malafronte P, Souza JF, Vilas Boas LS, Machado CM.

Transpl Infect Dis. 2012 Dec;14(6):564-74. doi: 10.1111/j.1399-3062.2012.00769.x. Epub 2012 Aug 13.

PMID:
22882692
9.

Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 Influenza virus vaccine coadministered with the seasonal 2009-2010 nonadjuvanted Influenza virus vaccine in HIV-infected children, adolescents, and young adults in a randomized controlled trial.

Viganò A, Giacomet V, Pariani E, Giani E, Manfredini V, Bedogni G, Erba P, Amendola A, Zanetti A, Zuccotti G.

Clin Vaccine Immunol. 2011 Sep;18(9):1503-9. doi: 10.1128/CVI.05200-11. Epub 2011 Jul 27.

10.

HIV virological suppression influences response to the AS03-adjuvanted monovalent pandemic influenza A H1N1 vaccine in HIV-infected children.

Leahy TR, Goode M, Lynam P, Gavin PJ, Butler KM.

Influenza Other Respir Viruses. 2014 May;8(3):360-6. doi: 10.1111/irv.12243. Epub 2014 Feb 18.

11.

Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults.

Hakim H, Allison KJ, Van De Velde LA, Li Y, Flynn PM, McCullers JA.

Vaccine. 2012 Jan 20;30(5):879-85. doi: 10.1016/j.vaccine.2011.11.105. Epub 2011 Dec 9.

PMID:
22155630
12.

Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults.

Crum-Cianflone NF, Iverson E, Defang G, Blair PJ, Eberly LE, Maguire J, Ganesan A, Faix D, Duplessis C, Lalani T, Whitman T, Brandt C, Macalino G, Millar EV, Burgess T.

Vaccine. 2011 Apr 12;29(17):3183-91. doi: 10.1016/j.vaccine.2011.02.040. Epub 2011 Mar 1.

13.

Unadjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected adults.

Hatakeyama S, Iwatsuki-Horimoto K, Okamoto K, Nukui Y, Yata N, Fujita A, Inaba S, Yotsuyanagi H, Kawaoka Y.

Vaccine. 2011 Nov 15;29(49):9224-8. doi: 10.1016/j.vaccine.2011.09.106. Epub 2011 Oct 5.

PMID:
21978767
14.

Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.

Lagler H, Wenisch JM, Tobudic S, Gualdoni GA, Rödler S, Rasoul-Rockenschaub S, Jaksch P, Redlberger-Fritz M, Popow-Kraupp T, Burgmann H.

Vaccine. 2011 Sep 16;29(40):6888-93. doi: 10.1016/j.vaccine.2011.07.050. Epub 2011 Jul 29.

PMID:
21803100
15.

Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy.

Pariani E, Boschini A, Amendola A, Poletti R, Anselmi G, Begnini M, Ranghiero A, Cecconi G, Zanetti AR.

Vaccine. 2011 Nov 15;29(49):9209-13. doi: 10.1016/j.vaccine.2011.09.103. Epub 2011 Oct 3.

PMID:
21974995
16.

Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination.

Soonawala D, Rimmelzwaan GF, Gelinck LB, Visser LG, Kroon FP.

PLoS One. 2011 Jan 31;6(1):e16496. doi: 10.1371/journal.pone.0016496.

17.

Phase 4 randomized trial of intradermal low-antigen-content inactivated influenza vaccine versus standard-dose intramuscular vaccine in HIV-1-infected adults.

Ansaldi F, Valle L, de Florentiis D, Parodi V, Murdaca G, Bruzzone B, Durando P, Setti M, Icardi G.

Hum Vaccin Immunother. 2012 Aug;8(8):1048-52. doi: 10.4161/hv.20347. Epub 2012 Aug 1.

18.

Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial.

Launay O, Desaint C, Durier C, Loulergue P, Duval X, Jacomet C, Pialoux G, Ghosn J, Raffi F, Rey D, Ajana F, Colin de Verdière N, Reynes J, Foubert V, Roman F, Devaster JM, Delfraissy JF, Aboulker JP; ANRS 151 HIFLUVAC Study Group and the French Clinical Vaccinology Network (Réseau National d'Investigation Clinique en Vaccinologie REIVAC).

J Infect Dis. 2011 Jul 1;204(1):124-34. doi: 10.1093/infdis/jir211.

19.

Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults.

Ikematsu H, Nagai H, Kawashima M, Kawakami Y, Tenjinbaru K, Li P, Walravens K, Gillard P, Roman F.

Hum Vaccin Immunother. 2012 Feb;8(2):260-6. doi: 10.4161/hv.18469. Epub 2012 Feb 1.

20.

Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults.

Nielsen AB, Nielsen HS, Nielsen L, Thybo S, Kronborg G.

Vaccine. 2012 Nov 19;30(49):7067-71. doi: 10.1016/j.vaccine.2012.09.052. Epub 2012 Oct 2.

PMID:
23036498

Supplemental Content

Support Center